قارن الطرق

	مقياس جودة الحياة لالتهاب المفاصل الصدفي (PsAQoL)	مؤشر وظائف التهاب الفقار اللاصق (BASFI)
المجال	أمراض الروماتيزم	أمراض الروماتيزم
العائلة	Process / pipeline	Process / pipeline
سنة النشأة	1997	1994
صاحب الطريقة	McKenna & Doherty	Calin et al.
النوع	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)
المصدر التأسيسي	Soderlin MK, Bergman S. Psychometric properties of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument: Rasch analysis. Arthritis Care Research. 2011;63(11):1589-1595.	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285.
الأسماء البديلة	PsAQoL, PSAQoL	BASFI, BAS-FI
ذات صلة	4	4
الملخص	The PsAQoL is a disease-specific patient-reported outcome measure of quality of life impact in psoriatic arthritis (PsA), a chronic inflammatory condition affecting joints and skin. Developed by McKenna and Doherty in 1997, PsAQoL comprises 20 items assessing the multidimensional impact of PsA on physical function, emotional well-being, work productivity, and social participation. PsAQoL captures the patient's lived experience of the disease, complementing clinical disease activity measures (CRP, joint counts) and providing a holistic view of treatment benefit in PsA research and practice.	The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.